Get the Stockscreener App
144.00
0.23%
0.33
After Hours:
144.00
Neurocrine Biosciences Inc stock is traded at $144.00, with a volume of 636.13K.
It is up +0.23% in the last 24 hours and down -1.82% over the past month.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
See More
Previous Close:
$143.67
Open:
$143.6
24h Volume:
636.13K
Relative Volume:
0.72
Market Cap:
$14.28B
Revenue:
$2.41B
Net Income/Loss:
$305.80M
P/E Ratio:
48.81
EPS:
2.95
Net Cash Flow:
$492.20M
1W Performance:
+2.79%
1M Performance:
-1.82%
6M Performance:
+36.16%
1Y Performance:
+24.65%
1-Day Range:
$142.20
$144.42
1-Week Range:
$138.78
$144.65
52-Week Range:
$84.23
$154.61
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
144.00 | 14.25B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
145.94 | 64.88B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.01 | 44.40B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.25 | 41.72B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.95 | 21.82B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
418.58 | 19.28B | 3.08B | 1.24B | 1.07B | 25.61 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Citigroup | Buy |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Apr-15-25 | Upgrade | Needham | Hold → Buy |
| Apr-14-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
How risky is Neurocrine Biosciences Inc. stock nowJuly 2025 Levels & Verified Chart Pattern Signals - newser.com
Will Neurocrine Biosciences Inc. (NB3) stock return to pre crash levels2025 Biggest Moves & Short-Term Trading Alerts - newser.com
Can Neurocrine Biosciences Inc. stock sustain revenue growth2025 Buyback Activity & Free Long-Term Investment Growth Plans - newser.com
Short interest data insights for Neurocrine Biosciences Inc.Weekly Loss Report & Risk Managed Investment Strategies - newser.com
Is Neurocrine Biosciences Inc. (NB3) stock a buy during volatile marketsPortfolio Update Summary & Verified High Yield Trade Plans - newser.com
Is Neurocrine Biosciences Inc a good long term investmentShort-Term Trading Alerts & You’ll Thank Yourself in 6 Months - earlytimes.in
Is Neurocrine Biosciences Inc. (NB3) stock vulnerable to rate hikes2025 Key Highlights & Consistent Return Investment Signals - newser.com
What moving averages say about Neurocrine Biosciences Inc.2025 Technical Overview & Free Risk Controlled Daily Trade Plans - newser.com
Examining Neurocrine Biosciences Valuation After 24% Stock Surge and Pipeline Progress in 2025 - Yahoo Finance
Neurocrine Biosciences Experiences Revision in Its Stock Evaluation Amid Strong Market Performance - Markets Mojo
Are You Looking for a Top Momentum Pick? Why Neurocrine Biosciences (NBIX) is a Great Choice - Yahoo Finance
3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX) - Yahoo Finance
Is Neurocrine Biosciences Inc. (NB3) stock a safe buy pre earningsProfit Target & AI Based Trade Execution Alerts - newser.com
Did Positive KINECT 4 Data Just Shift Neurocrine Biosciences' (NBIX) Investment Narrative? - simplywall.st
Full technical analysis of Neurocrine Biosciences Inc. stockMarket Weekly Review & Low Risk Growth Stock Ideas - newser.com
Can Neurocrine Biosciences Inc. stock maintain growth trajectory2025 Analyst Calls & Daily Technical Forecast Reports - newser.com
What analysts say about Neurocrine Biosciences Inc NB3 stockBollinger Bands Signals & Daily Tips From Top Market Analysts - earlytimes.in
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Citigroup Initiates Coverage of Neurocrine Biosciences (NBIX) with Buy Recommendation - Nasdaq
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):